Sarcomas of the Uterine Cervix: A United and Multidisciplinary Approach is Required

Khosla, Divya; Patel, Firuza D.; Kumar, Ritesh

doi:10.2217/whe.13.59

Cited by 2 publications

(1 citation statement)

References 20 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately only 80 cases have been reported in the English literature so far , and 128 cases have been documented according to the National Cancer Institute's Surveillance, Epidemiology, and End Results database . Owing to their rarity, cervical carcinosarcomas have not been well characterized, and currently there is no standard of care for this disease . A recent meta‐analysis revealed that the 2‐year disease‐free survival and overall survival were 49% and 60%, respectively .…”

Section: Introductionmentioning

confidence: 99%

Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report

Zhu

Liu

et al. 2019

The Oncologist

View full text Add to dashboard Cite

Cervical carcinosarcoma is an extremely rare type of neoplasm that lacks standard of care. Preclinical and clinical evidence has suggested that cryoablation in combination with immunotherapy may result in a synergistic effect, generating a more robust immune response to distant lesions. A few clinical trials have evaluated the efficacy of such combination treatment in a variety of solid tumors, but with conflicting results. This report describes the first clinical efficacy of cryoablation followed by pembrolizumab observed in a patient with tumor mutational burden (TMB)-high metastatic cervical carcinosarcoma that was negative for programmed cell death protein 1 expression, microsatellite instability stable, and had mutations in DNA polymerase epsilon (POLE). She had achieved complete response (CR) after 3 months of pembrolizumab treatment and had maintained CR as of the time of submission of this manuscript, with a progression-free survival of 11 months and counting. The case exhibited an exceptional response to cryoablation followed by pembrolizumab, potentially attributed to mutations in POLE, which lead to an extremely high TMB. This report paves the avenue for establishing treatment regimens for patients with TMB-high cervical carcinosarcoma. The Oncologist 2020;25:15-18 KEY POINTS• Owing to its rarity, cervical carcinosarcoma has not been well characterized, and currently, there is no standard of care for this disease. • This report describes the first case of clinical efficacy of cryoablation followed by pembrolizumab observed in a patient with tumor mutational burden-high metastatic cervical carcinosarcoma. • The case exhibited an exceptional response (maintained CR as of the time of submission of this article: 11 months) to cryoablation followed by pembrolizumab. • This is the first POLE-mutated cervical carcinosarcoma case.

show abstract

Section: Introductionmentioning

confidence: 99%